Trial of treatment of vaginal intraepithelial neoplasia (VAIN)

ISRCTN ISRCTN23349576
DOI https://doi.org/10.1186/ISRCTN23349576
Secondary identifying numbers N/A
Submission date
16/12/2015
Registration date
18/01/2016
Last edited
01/11/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Human papilloma virus (HPV) is the name used to refer to a group of viruses that can affect the skin and the moist membranes lining the body, for example the cervix, mouth and throat. Genital HPV can cause abnormal tissue growth (lesions) and other changes to cells within the cervix, vagina and vulva. This can sometimes lead to cervical cancer. These abnormalities can usually be detected with a Pap (cervical) smear. The majority of lesions caused by HPV do not need to be treated, but a prolonged infection over a number of years can lead to precancerous changes and eventually cancer. Lesions in the vagina (vaginal intraepithelial neoplasia, VAIN) are usually treated with laser ablation (removal of the lesion using a laser) or surgical removal of the affected part of the vagina. The disease can be chronic (long lasting) requiring repeated treatment. The treatment can also be difficult due to multifocal lesions (lesions in more than one region of the vagina). A cream containing imiquimod is used to treat genital warts locally. Genital warts are lesions caused by certain HPV types and are benign. Imiquimod is an immunomodulator, which means it stimulates the body’s own immune response to the infection. Imiquimod has already been studied in the treatment of other genital lesions caused by HPV. The results have been promising and vaginally administered imiquimod has been relatively well tolerated. This study is looking at different treatment options for vaginal intraepithelial neoplasias (VAIN). The aim of the study is to see how well tolerated and how successful these treatments are.

Who can participate?
Women over 18 that have been diagnosed with VAIN.

What does the study involve?
Participants have an HPV sample taken (with a brush) in addition to routine samples during an outpatient colposcopy visit. They are then randomized into one of two groups. Those in group 1 are treated laser ablation. Those in group 2 are treated with vaginally administered imiquimod. The imiquimod is given as suppositories which are used at home 1-2 times a week for two months (the single dose of imiquimod is 12.5 mg which can be halved if severe side effects occur). The follow-up in the study includes visits at the colposcopy clinic at 2, 4 and 6 months after the initial visit. If persistence or progression of the lesion is detected at the 4-month-visit, the patient is offered either laser ablation or surgery for treatment.

What are the possible benefits and risks of participating?
The frequent follow-ups for the duration of this study can benefit the patients participating. Participation in the study is not likely to cause any harm to the patient even if the treatment method would have to be changed during the course of the study. Due to the short duration of the study no significant delay in treatment will occur. Side effects of imiquimod can be local irritation, lower abdominal pain and flu-like symptoms or fever. These side effects can be treated with non-steroidal anti-inflammatory drugs (NSAIDs).

Where is the study run from?
Helsinki University Hospital, Women's Hospital.

When is the study starting and how long is it expected to run for?
September 2015 to December 2020.

Who is funding the study?
Research Council for Health (Finland)

Who is the main contact?
Dr Annika Riska
annika.riska@hus.fi

Contact information

Dr Annika Riska
Scientific

Haartmaninkatu 2
Helsinki
00290
Finland

Phone +35894711
Email annika.riska@hus.fi

Study information

Study designSingle center randomized interventional trial
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleRandomized trial of treatment of vaginal intraepithelial neoplasia (VAIN): laser vaporization and imiquimod
Study objectivesThis randomized trial aims to assess the efficacy of treatment of VAIN with traditional laser vaporization or vaginally administered imiquimod. Efficacy will be assessed by histological regression and HPV clearance. We have conducted a pilot trial on this subject (ISRCTN45751386) which found laser and imiquimod treatment to be equally effective in regard to histological regression, but imiquimod was significantly more effective in achieving HPV clearance. This study has power estimations based on the pilot trial.
Ethics approval(s)Helsinki University Hospital Ethical Committee, 26/11/2015, ref: 339/13/03/03/2015
Health condition(s) or problem(s) studiedVaginal intraepithelial neoplasia (VAIN)
InterventionPatients enrolled in the study will have an HPV sample taken (with a brush) in addition to the routine samples during an outpatient colposcopy visit. Enrolled patients will be randomized into two groups:

Group 1: treated by laser ablation
Group 2: treated with vaginally administered imiquimod

The imiquimod is given as suppositories which are used at home 1-2 times a week for two months (the single dose of imiquimod is 12.5 mg which can be halved if severe side effects occur). The follow-up in the study includes visits at the colposcopy clinic at 2, 4 and 6 months after the initial visit. If persistence or progression of the lesion is detected at the 4-month-visit, the patient is offered either laser ablation or surgery for treatment.
Intervention typeMixed
Primary outcome measure1. Histological regression (defined as VAIN 1 or less), assessed from punch biopsies
2. HPV clearance, assessed via HPV genotyping from cervical or vaginal brush samples

Measured at 2, 4 and 6 months
Secondary outcome measures1. Complete histological regression, assessed from punch biopsies
2. Tolerability of treatment, assessed based on adverse effect reporting on a standardized form from the patients

Measured at 2, 4 and 6 months
Overall study start date01/09/2015
Completion date31/12/2020

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexFemale
Target number of participantsTotal recruitment target 60 patients.
Key inclusion criteria1. Over 18 years of age
2. Histological diagnosis of VAIN 2-3
3. Histological diagnosis of VAIN 1, which has been expectantly managed for two years
Key exclusion criteria1. Pregnancy or lactation
2. Lack of reliable contraception in premenopausal patients
3. Known HIV infection
4. Vaginal cancer
Date of first enrolment01/01/2016
Date of final enrolment31/12/2020

Locations

Countries of recruitment

  • Finland

Study participating centre

Helsinki University Hospital, Women's Hospital
Helsinki
00610
Finland

Sponsor information

Helsinki University Hospital, Women's Hospital
Hospital/treatment centre

Haartmaninkatu 2
Helsinki
00290
Finland

Phone +35894711
Email annika.riska@hus.fi
ROR logo "ROR" https://ror.org/02e8hzf44

Funders

Funder type

Research council

Terveyden Tutkimuksen Toimikunta
Private sector organisation / Universities (academic only)
Alternative name(s)
Research Council for Health, Forskningsrådet för Hälsa
Location
Finland

Results and Publications

Intention to publish date31/12/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planWe intend to publish results of the outcome measures when the trial is completed.
IPD sharing plan

Editorial Notes

01/11/2017: Internal review.